Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer – EORTC 08062

• Published in: European journal of cancer (1990) Vol. 47; no. 15; pp. 2322 - 2330
• Main Authors: O’Brien, Mary E.R, Konopa, Krzystof, Lorigan, Paul, Bosquee, Lionel, Marshall, Ernest, Bustin, Frederique, Margerit, Sabine, Fink, Christian, Stigt, Jos A, Dingemans, Anne Marie C, Hasan, Baktiar, Van Meerbeeck, Jan, Baas, Paul
• Format: Journal Article
• Language: English
• Published: Kidlington Elsevier Ltd 01.10.2011; Elsevier
• Subjects: Adult; Aged; Amrubicin; Anthracyclines - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - mortality; Carcinoma, Non-Small-Cell Lung - pathology; Cisplatin - administration & dosage; Disease-Free Survival; Etoposide - administration & dosage; Europe; Female; Hematology, Oncology and Palliative Medicine; Humans; Lung Neoplasms - drug therapy; Lung Neoplasms - mortality; Lung Neoplasms - pathology; Male; Medical sciences; Middle Aged; Pharmacology. Drug treatments; Small cell lung cancer; Survival; Survival Analysis; Survival Rate; Time Factors; Toxicity; Treatment Outcome; Tumors; Europe; Amrubicin; Small cell lung cancer; Toxicity; Survival; Antineoplastic agent; Lung cancer; Bonchopulmonary small cell carcinoma; Podophyllotoxin derivatives; Randomization; Isomerases; Cancerology; Phase II trial; Bronchus disease; Antimitotic; Platinum II Complexes; Human; DNA topoisomerase (ATP-hydrolysing); Lung disease; Drug combination; Enzyme; Respiratory disease; Enzyme inhibitor; Etoposide; Topoisomerase II inhibitor; Malignant tumor; Cisplatin; First line treatment; Alkylating agent; Clinical stage; Anthracyclins; Comparative study; Cancer; European Organization for Research and Treatment of Cancer

Abstract Purpose The EORTC 08062 phase II randomised trial investigated the activity and safety of single agent amrubicin, cisplatin combined with amrubicin, and cisplatin combined with etoposide as first line treatment in extensive disease (ED) small cell lung cancer (SCLC). Patients and methods El...